Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited (PBIGF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pbigf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Paradigm Biopharmaceuticals LimitedYou PBIGF | $46M | N/A | — | -$0.09 |
 Nuo Therapeutics, Inc. AURX | $48M | N/A | — | -$0.05 |
 Imugene Limited IUGNF | $43M | N/A | — | -$0.32 |
 Kintor Pharmaceutical Limited KNTPF | $265M | N/A | — | -$0.43 |
 Satellos Bioscience Inc. MSCLF | $97M | N/A | — | -$20.45 |
 Orexo AB (publ) ORXOF | $102M | N/A | — | -$3.74 |
 Pacific Edge Limited PFGTF | $188M | N/A | — | -$0.04 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Paradigm Biopharmaceuticals Limited (PBIGF) measures how much investors pay for each dollar of the company's trailing earnings. PBIGF's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$0.09.
Frequently asked questions
PBIGF pe ratio · 6 questionsPBIGF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.10 and TTM EPS of -$0.09. Data sourced from Financial Modeling Prep via PBIGF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Paradigm Biopharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09